UnitedHealthCare

The private payor published new coverage criteria for whole-genome sequencing tests for patients with a variety of non-cancer indications.

The private payor added new coverage criteria for sequencing tests in approved companion diagnostic indications, as well as prostate cancer risk assays.

The move adds coverage for patients not eligible for coverage under Medicare, which currently pays for the test across all tumor types.